Epigenetic activation of E-cadherin is a candidate therapeutic target in human hepatocellular carcinoma

Experimental and Therapeutic Medicine

Volumn 1, Issue 3, 2010, Pages 519-523

  Qiu, Xuemei ^a   Qiao, Fengchang ^a   Su, Xianwei ^a   Zhao, Zhujiang ^a   Fan, Hong ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

5 azacytidine; E cadherin; HBx; siRNA; Trichostatin A

Indexed keywords

AZACITIDINE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HEPATITIS B VIRUS X PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; TRICHOSTATIN A; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; PROMOTER REGION; PROTEIN EXPRESSION; UPREGULATION;

EID: 77956192512     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000082     Document Type: Article

References (33)

1. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455, 1991.
2. Hirohashi S and Kanai Y: Cell adhesion system and human cancer morphogenesis. Cancer Sci 94: 575-581, 2003.
3. Momparler RL and Bovenzi V: DNA methylation and cancer. J Cell Physiol 183: 145-154, 2000.
4. Hazan RB, Qiao R, Keren R, Badano I and Suyama K: Cadherin switch in tumor progression. Ann NY Acad Sci 1014: 155-163, 2004.
5. Calvisi DF, Ladu S, Conner EA, Factor VM and Thorgeirsson SS: Disregulation of E-cadherin in transgenic mouse models of liver cancer. Lab Invest 84: 1137-1147, 2004.
6. Huang GT, Lee HS, Chen CH, Sheu JC, Chiou LL and Chen DS: Correlation of E-cadherin expression and recurrence of hepatocellular carcinoma. Hepatogastroenterology 46: 1923-1927, 1999.
7. Wei Y, van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P and Buendia MA: Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression and clinical features. Hepatology 36: 692-701, 2002.
8. Ihara A, Koizumi H, Hashizume R and Uchikoshi T: Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinoma. Hepatology 23: 1441-1447, 1996.
9. Howard EW, Camm KD, Wong YC and Wang XH: E-cadherin upregulation as a therapeutic goal in cancer treatment. Mini Rev Med Chem 8: 496-518, 2008.
10. Liu J, Lian Z, Han S, Waye MM, Wang H, Wu MC, Wu K, Ding J, Arbuthnot P, Kew M, Fan D and Feitelson MA: Downregulation of E-cadherin by hepatitis B virus Xantigen in hepatocellullar carcinoma. Oncogene 25: 1008-1017, 2006.
11. Yoo CB and Jones PA: Epigenetic therapy of cancer: past, present and future: Nat Rev Drug Discov 5: 37-50, 2006.
12. Fan H, Zhao Z, Quan Y, Xu J, Zhang J and Xie W: DNA methyltransferase 1 knockdown induces silenced CDH1 gene reexpression by demethylation of methylated CpG in hepatocellular carcinoma cell line SMMC-7721. Eur J Gastroenterol Hepatol 19: 952-961, 2007.
13. Xu J, Fan H, Zhao ZJ, Zhang JQ and Xie W: Identification of potential genes regulated by DNAmethyltransferase 3B in a hepatocellular carcinoma cell line by RNAinterference and microarray analysis. Yi Chuan Xue Bao 32: 1115-1127, 2005.
14. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA93: 9821-9826, 1996.
15. Zhang H, Xiao W, Liang H, Fang D, Yang S and Luo Y: Demethylation in the promoter area by the antisense of human DNAMTase gene. Zhonghua Zhong Liu Za Zhi 24: 444-447, 2002.
16. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M and Hirohashi S: The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer 71: 355-359, 1997.
17. Feitelson M: Hepatitis B virus infection and primary hepatocellular carcinoma. Clin Microbiol Rev 5: 275-301, 1992.
18. Murakami Y, Hayashi K and Sekiya T: Aberration of the tumor suppressor p53 and retinoblastoma in human hepatocellular carcinomas. Cancer Res 51: 5520-5525, 1991.
19. Liao C, Zhao M, Song H, Uchida K, Yokoyama KK and Li T: Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. Hepatology 32: 721-727, 2000.
20. Constantinides PG, Jones PA and Gevers W: Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 267: 364-366, 1977.
21. Yoshida M, Horinouchi S and Beppu T: Trichostatin Aand trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17: 423-430, 1995.
22. Zhu WG and Otterson GA: The interaction of histone deacetylase inhibitors and DNAmethyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti-Cancer Agents 3: 187-199, 2003.
23. Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, Kato M, Seki N and Saisho H: Identification of genes up-regulated by histone deacetylase inhibition with cDNAmicroarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 41: 436-445, 2004.
24. Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F and Cornelisse C: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13: 1919-1925, 1996.
25. Melki JR, Vincent PC, Brown RD and Clark SJ: Hypermethylation of E-cadherin in leukemia. Blood 95: 3208-3213, 2000.
26. Tamura G, Yin J, Wang S, et al: E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 92: 569-573, 2000.
27. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, Satoh T, Toyota J, Satoh M, Endo T and Imai K: Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19: 5298-5302, 2000.
28. Nam JS, Ino Y, Kanai Y, Sakamoto M and Hirohashi S: 5-aza-2'-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis. Clin Exp Metastasis 21: 49-56, 2004.
29. Yu MC, Yuan JM, Govindarajan S and Ross RK: Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 14: 703-709, 2000.
30. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T and Jacob ST: 5-Aza-deoxycytidine induces selective degradation of DNAmethyltransferase 1 by a proteasomal pathway that requires the KENbox, bromo-adjacent homology domain and nuclear localization signal. Mol Cell Biol 25: 4727-4741, 2005.
31. Palii SS, van Emburgh BO, Sankpal UT, Brown KD and Robertson KD: DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNAdamage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 28: 752-771, 2008.
32. Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH, Surzycki SJ and Lee YI: Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus Xprotein. Gastroenterology 132: 1476-1494, 2007.
33. Zheng DL, Zhang L, Cheng N, Xu X, Deng Q, Teng XM, Wang KS, Zhang X, Huang J and Han ZG: Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 50: 377-387, 2009.